Fig. 2 | British Journal of Cancer

Fig. 2

From: Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Fig. 2

Waterfall plot (a) of individual patient target lesion best response, swimmers plot (b) of time on study by tissue type, and select patient oncoprint heatmap (c) by whole-exome sequencing. NSCLC non-small cell lung carcinoma, NET neuroendocrine tumour, SCLC small cell lung carcinoma, EHE epithelioid hemangioepithelioma, ID study identification number. *a (waterfall)—Of the 49 efficacy-evaluable patients, 3 patients had progressive disease (described in the section “Efficacy evaluation”) but no target lesion measurement (not included in waterfall plot)

Back to article page